Respiratory tract infection

Technology Being Challenged by Upsurge in Decentralized Clinical Trials

Retrieved on: 
Tuesday, April 5, 2022

MANASSAS, Va., April 5, 2022 /PRNewswire-PRWeb/ -- Clinical trials in certain common serious diseases are on track for their first year-over-year increase since the outbreak of the COVID-19 pandemic. Among areas slated for significantly increased testing are diabetes, hypertension, and respiratory tract infection. Along with these activities will come a marked increase in decentralized clinical trial design, expected to increase 28% this year over 2021.(1) "By joining forces to enable the increased growth of decentralized studies," says Dr. Harsha Rajasimha, founder and CEO of Jeeva Informatics, "technology companies are transforming the face of medical research. The remotely managed, decentralized clinical trial is the wave of the future."

Key Points: 
  • There has been, he notes, a growing awareness of the need for decentralized clinical trials for some time.
  • A few years back, for example, the National Academies of Sciences convened a forum on transforming clinical trials through technology.
  • New technology such as wearable devices, remote monitoring, and virtual clinical visits could make Clinical Trials more patient-focused.
  • The accelerated process used for COVID-19 trials has conclusively demonstrated both the need for and the efficacy of decentralized clinical trials.

argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

Retrieved on: 
Tuesday, March 22, 2022

In a clinical study, the most common infections were urinary tract and respiratory tract infections.

Key Points: 
  • In a clinical study, the most common infections were urinary tract and respiratory tract infections.
  • More patients on VYVGART vs placebo had below normal levels for white blood cell counts, lymphocyte counts, and neutrophil counts.
  • Your health care provider should check you for infections before starting treatment, during treatment, and after treatment with VYVGART.
  • The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises.

Global Respiratory Partnering Directory/Report 2021: Comprehensive Access to 850+ Deal Records - Deal Trends, Players and Financials - ResearchAndMarkets.com

Retrieved on: 
Monday, March 14, 2022

The "Global Respiratory Partnering 2010-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Respiratory Partnering 2010-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Respiratory Partnering 2010 to 2021 report provides comprehensive access to available deals and contract documents for over 850 respiratory deals.
  • The report takes readers through the comprehensive Respiratory disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Respiratory deals.
  • Global Respiratory Partnering 2010 to 2021 includes:
    In Global Respiratory Partnering 2010 to 2021, available deals and contracts are listed by:

Air Purifier Market Size Worth $25.97 Billion by 2030 | CAGR: 8.1%: Grand View Research, Inc.

Retrieved on: 
Thursday, February 24, 2022

SAN FRANCISCO, Feb. 24, 2022 /PRNewswire/ -- The global air purifier market size is expected to reach USD 25.97 billion by 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Feb. 24, 2022 /PRNewswire/ -- The global air purifier market size is expected to reach USD 25.97 billion by 2030, according to a new report by Grand View Research, Inc.
  • Air purifiers assist in eliminating various health hazards caused by poor air quality by removing contaminants, including dust, smoke, and pollen.
  • The pandemic provided an opportunity for companies with higher cashflows to acquire air purifier companies resulting in increased activity in the market.
  • Grand View Research has segmented the global air purifier market on the basis of technology, application, and region:
    Air Purifier Technology Outlook (Revenue, USD Million, 2017 - 2030)

Air Purifier Market Size Worth $25.97 Billion by 2030 | CAGR: 8.1%: Grand View Research, Inc.

Retrieved on: 
Thursday, February 24, 2022

SAN FRANCISCO, Feb. 24, 2022 /PRNewswire/ -- The global air purifier market size is expected to reach USD 25.97 billion by 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Feb. 24, 2022 /PRNewswire/ -- The global air purifier market size is expected to reach USD 25.97 billion by 2030, according to a new report by Grand View Research, Inc.
  • Air purifiers assist in eliminating various health hazards caused by poor air quality by removing contaminants, including dust, smoke, and pollen.
  • The pandemic provided an opportunity for companies with higher cashflows to acquire air purifier companies resulting in increased activity in the market.
  • Grand View Research has segmented the global air purifier market on the basis of technology, application, and region:
    Air Purifier Technology Outlook (Revenue, USD Million, 2017 - 2030)

FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease

Retrieved on: 
Friday, February 4, 2022

Enjaymo is the only approved treatment to inhibit red blood cell destruction in CAD and help stop the chain reaction from the start.

Key Points: 
  • Enjaymo is the only approved treatment to inhibit red blood cell destruction in CAD and help stop the chain reaction from the start.
  • For the first time, we have a treatment that targets complement-mediated hemolysis, which is the underlying cause of the red blood cell destruction in many CAD patients.
  • Dosage interruptions due to an adverse reaction occurred in 17 percent (4/24) of patients who received Enjaymo.
  • Following the completion of the 26-week treatment period of CARDINAL (Part A), eligible patients continued to receive Enjaymo in an extension study.

argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

Retrieved on: 
Friday, December 17, 2021

More patients on VYVGART vs placebo had below normal levels for white blood cell counts, lymphocyte counts, and neutrophil counts.

Key Points: 
  • More patients on VYVGART vs placebo had below normal levels for white blood cell counts, lymphocyte counts, and neutrophil counts.
  • Your health care provider should check you for infections before starting treatment, during treatment, and after treatment with VYVGART.
  • Discuss with your health care provider whether you need to receive age-appropriate immunizations before initiation of a new treatment cycle with VYVGART.
  • VYVGART is approved in the United States for the treatment of adults with generalized myasthenia gravis (gMG), who are anti-AChR antibody positive.

Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update

Retrieved on: 
Friday, December 10, 2021

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first positive interim data from the Phase 1 study of the Companys quadrivalent seasonal flu vaccine candidate, mRNA-1010.

Key Points: 
  • Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first positive interim data from the Phase 1 study of the Companys quadrivalent seasonal flu vaccine candidate, mRNA-1010.
  • Moderna also provided an update on its seasonal flu vaccine program including the announcement of two beyond quadrivalent seasonal flu development candidates (mRNA-1011 and mRNA-1012).
  • The positive interim results from our Phase 1 quadrivalent flu vaccine candidate, mRNA-1010, are an important milestone toward achieving that goal.
  • Modernas RSV vaccine candidate (mRNA-1345) demonstrated positive Phase 1 results and the Companys Phase 2/3 study is ongoing.

Global Immune Health Supplements Market Trends Analysis Report 2021-2028, By Product, Form, Application, Mode Of Medication and Distribution Channel - ResearchAndMarkets.com

Retrieved on: 
Friday, October 22, 2021

The "Immune Health Supplements Market Size, Share & Trends Analysis Report By Product, By Form, By Application, By Mode Of Medication, By Distribution Channel, By Region, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Immune Health Supplements Market Size, Share & Trends Analysis Report By Product, By Form, By Application, By Mode Of Medication, By Distribution Channel, By Region, And Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global immune health supplements market size is expected to reach USD 132.0 billion by 2028.
  • However, taking dietary supplements among individuals for immune health has been increased from 27 percent to 32 percent from 2019 to 2020.
  • Global Immune Health Supplements Market Variables, Trends & Scope

Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus (RSV) Vaccine in Older Adults

Retrieved on: 
Wednesday, September 29, 2021

"With no vaccine or broadly-indicated antiviral treatment available, preventive solutions to address the significant morbidity and mortality in older adults caused by RSV have long been an unmet need."

Key Points: 
  • "With no vaccine or broadly-indicated antiviral treatment available, preventive solutions to address the significant morbidity and mortality in older adults caused by RSV have long been an unmet need."
  • Respiratory syncytial virus (RSV) is a prevalent, highly contagious respiratory virus and a leading cause of bronchitis, bronchiolitis and pneumonia, affecting more than 64 million people worldwide in a typical year.
  • Between 3-7 percent of older adults (age 60 and older) and 4-10 percent of high-risk adults (age 18 and older) experience RSV in a typical year.
  • Trial participants will be randomized to receive either one dose of active investigational vaccine or placebo.